D
X4 Pharmaceuticals, Inc. XFOR
$3.83 -$0.05-1.16% NASDAQ
Recommendation
Prev Close
$3.87
Volume
34,137
Avg Vol (90D)
3,317,034
Market Cap
$338.38M
Dividend & Yield
--
52-Week Range
$1.35 - $26.83
P/E (TTM)
--
EPS (TTM)
-$10.01
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Critical Contrast: Poxel France (OTCMKTS:PXXLF) and X4 Pharmaceuticals (NASDAQ:XFOR)
11/12/2025 - Ticker Report
X4 Pharmaceuticals (XFOR, $3.63) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 10, 2025
11/11/2025 - Tickeron - Stocks
X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright
11/10/2025 - TipRanks Financial Blog
X4 Pharmaceuticals price target raised by $1.50 at H.C. Wainwright, here's why
11/10/2025 - The Fly
X4 Pharmaceuticals (XFOR, $3.71) entered Downtrend as Momentum indicator drops below 0 level on Nov 07, 2025
11/8/2025 - Tickeron - Stocks
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in X4 Pharmaceuticals Inc
11/8/2025 - GuruFocus
X4 Pharmaceuticals (NASDAQ:XFOR) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS
11/7/2025 - Ticker Report
X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference
11/5/2025 - GuruFocus
X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference
11/5/2025 - Globe Newswire
X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel
11/5/2025 - TipRanks Financial Blog
X4 Pharmaceuticals price target lowered by $1.50 at Stifel, here's why
11/5/2025 - The Fly
MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11/5/2025 - Zacks Investment Research
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates
11/5/2025 - Zacks Investment Research
Techne (TECH) Meets Q1 Earnings Estimates
11/5/2025 - Zacks Investment Research
X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)
11/5/2025 - The Fly
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/5/2025 - GuruFocus
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
11/5/2025 - Globe Newswire
X4 Pharmaceuticals (XFOR, $3.97) RSI Indicator left the overbought zone on November 04, 2025
11/5/2025 - Tickeron - Stocks
X4 Pharmaceuticals (XFOR, $3.99) RSI Indicator left the overbought zone on October 30, 2025
10/31/2025 - Tickeron - Stocks
Video: Tuesday 10/28 Insider Buying Report: CRMD, XFOR
10/28/2025 - Market News Video
X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Acquires $249,997.40 in Stock
10/28/2025 - MarketBeat
Empery Asset Management, LP's Strategic Acquisition in X4 Pharmaceuticals Inc
10/28/2025 - GuruFocus
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' ...
10/28/2025 - GuruFocus
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million
10/27/2025 - Globe Newswire
X4 Pharmaceuticals 45.87M share Spot Secondary priced at $2.85
10/24/2025 - The Fly
Income Statement
Total Revenue (TTM)
$33.98M
EBITDA (TTM)
-$92.67M
EBIT (TTM)
-$94.00M
Net Income (TTM)
-$95.10M
Balance Sheet
Total Assets (Q)
$163.56M
Total Debt (Q)
$77.36M
Total Liabilities (Q)
$101.94M
Book Value Per Share (Q)
$2.45
Cash Flow
Cash from Operations (TTM)
-$103.09M
Cash from Investing (TTM)
-$17.32M
Cash from Financing (TTM)
$92.67M
Net Change in Cash (TTM)
-$27.77M
Filings
Filing Date
Wednesday, November 5, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Mar 23 and 27 (est)
Price History
Loading...
Beta
2.18
7-Day Total Return
-3.65%
30-Day Total Return
9.91%
60-Day Total Return
36.61%
90-Day Total Return
130.42%
Year to Date Total Return
-83.05%
1-Year Total Return
-54.02%
2-Year Total Return
-83.22%
3-Year Total Return
-93.32%
5-Year Total Return
-98.02%
52-week Low
Aug 11, 2025 - $1.35
52-week High
Dec 31, 2024 - $26.83
Valuation
Market Cap
$338.38M - Small Cap
Enterprise Value
$293.54M
Price/Sales (TTM)
4.93
Price/Book (Q)
1.58
Dividends and Shares
Shares Outstanding
43.27
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.x4pharma.com
Phone Number
857 529 8300
Address
61 North Beacon Street
Boston, MA 02134
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system... more
NASDAQ 11/13/2025 10:24AM Eastern Quotes delayed